http://medicalxpress.com/ en-us Medical Xpress internet news portal provides the latest news on Health and Medicine. (HealthDay)—Monica Barlow, a 35-year-old from Maryland, was training for a half-marathon when she noticed she couldn't shake a bad cough and ongoing fatigue. After a couple of rounds of antibiotics from an urgent care clinic didn't work, she sought another opinion. http://medicalxpress.com/news/2013-04-clinical-trials-woman-cancer.html Cancer Thu, 18 Apr 2013 13:19:19 EST news285509952 Platinum compounds, such as cisplatin and carboplatin, induce DNA cross-linking, prohibiting DNA synthesis and repair in rapidly dividing cells. They are first line therapeutics in the treatment of many solid tumors, but cancer cells frequently develop resistance to these drugs. http://medicalxpress.com/news/2013-04-resistance-futile-gene-cisplatin-ovarian.html Cancer Mon, 15 Apr 2013 12:00:09 EST news285240110 Breast cancers that lack estrogen receptors are more difficult to treat than ER+ cancers. Research presented at the AACR Annual Meeting 2013 demonstrates an investigational drug, Paragazole, that makes triple-negative breast cancer cells express estrogen receptors, and that increases the sensitivity of these cells to chemotherapy. http://medicalxpress.com/news/2013-04-paragazole-excels-preclinical-triple-negative-breast.html Cancer Mon, 08 Apr 2013 09:16:30 EST news284631363 More than half of all patients with ovarian cancer experience recurrent disease and will eventually fail to respond to chemotherapy. The failure of chemotherapy is usually due to the development of resistance to the two main classes of chemotherapy agents used to fight it – platinating agents and taxanes. Now, a study reported in the open-access Journal of Ovarian Research provides novel information that further adds to clinicians' understanding of the mechanisms involved in the development of resistance to dual-agent chemotherapy. http://medicalxpress.com/news/2012-11-mechanisms-drug-resistance-dual-agent-chemotherapy.html Cancer Thu, 29 Nov 2012 19:00:01 EST news273434985 (HealthDay)—A phase I trial of dasatinib combined with paclitaxel and carboplatin has determined the optimal dose of dasatinib and suggested some efficacy in women with advanced or recurrent ovarian cancer, according to research published in the Oct. 1 issue of Clinical Cancer Research. http://medicalxpress.com/news/2012-11-optimal-dose-dasatinib-ovarian-cancer.html Cancer Mon, 19 Nov 2012 10:00:13 EST news272540632 (HealthDay)—Abraxane (paclitaxel protein-bound) has been approved by the U.S. Food and Drug Administration—in combination with the drug carboplatin—to treat advanced or spreading non-small cell lung cancer among people who aren't candidates for surgery or radiation therapy, the agency said Friday. http://medicalxpress.com/news/2012-10-abraxane-advanced-lung-cancer.html Cancer Sun, 14 Oct 2012 06:33:08 EST news269415178 New cancer drugs must be thoroughly tested in preclinical models, often in mice, before they can be offered to cancer patients for the first time in phase I clinical trials. Key components of this process include pharmacokinetic and pharmacodynamic studies, which evaluate how the drug acts on a living organism. These studies measure the pharmacologic response and the duration and magnitude of response observed relative to the concentration of the drug at an active site in the organism. http://medicalxpress.com/news/2012-09-genetically-engineered-preclinical-pharmacodynamic-response.html Cancer Wed, 19 Sep 2012 13:18:12 EST news267279479 (Medical Xpress)—Researchers from the University of Dundee have discovered that measuring how active a gene is could predict which women with ovarian cancer will benefit from platinum-based chemotherapy drugs - a common treatment for the disease. http://medicalxpress.com/news/2012-09-gene-ovarian-cancer-benefit-chemotherapy.html Cancer Wed, 19 Sep 2012 07:39:15 EST news267259149 (HealthDay) -- For patients with non-small-cell lung cancer (NSCLC) who undergo neoadjuvant platinum-based chemotherapy, tissue platinum concentrations correlate positively with improved outcome, according to a study published online Aug. 13 in the Journal of Clinical Oncology. http://medicalxpress.com/news/2012-08-tissue-platinum-linked-response-nsclc.html Cancer Tue, 14 Aug 2012 18:10:01 EST news264183905 (HealthDay) -- For patients with esophageal or esophagogastric-junction cancer, treatment with neoadjuvant chemoradiotherapy followed by surgical resection is associated with improved survival compared with surgery alone, according to a study published in the May 31 issue of the New England Journal of Medicine. http://medicalxpress.com/news/2012-05-pre-op-chemoradiotherapy-ups-survival-esophageal.html Cancer Thu, 31 May 2012 10:20:01 EST news257675383 Analysis of a drug regimen approved by the F.D.A. in 2006 for the treatment of non-small cell lung cancer (bevacizumab added to the standard chemotherapy regimen carboplatin and paclitaxel) finds Medicare insured patients age 65 years and older who received this regimen did not have improved survival compared to patients who received the standard treatment of carboplatin and paclitaxel alone, according to a study in the April 18 issue of JAMA, a theme issue on comparative effectiveness research. http://medicalxpress.com/news/2012-04-drug-regimen-treatment-non-small-cell.html Cancer Tue, 17 Apr 2012 10:51:03 EST news253878657 A naturally-occurring harmless human virus may be able to boost the effects of two standard chemotherapy drugs in some cancer patients, according to early stage trial data published in Clinical Cancer Research. http://medicalxpress.com/news/2012-04-harmless-human-virus-boost-effects.html Cancer Tue, 03 Apr 2012 16:53:50 EST news252690820 A combination of nab-paclitaxel and carboplatin for the treatment of non-small cell lung cancer may be a promising option for patients ineligible for treatment with bevacizumab, according to data presented at the AACR Annual Meeting 2012, held here March 31 - April 4. http://medicalxpress.com/news/2012-04-drug-combination-option-patients-nsclc.html Cancer Tue, 03 Apr 2012 09:42:16 EST news252664926 (HealthDay) -- Retinoblastoma patients who are younger than 6 months of age at the start of carboplatin treatment experience a higher incidence of ototoxicity, according to a study published online Feb. 27 in the Journal of Clinical Oncology. http://medicalxpress.com/news/2012-02-ototoxicity-children-carboplatin.html Cancer Wed, 29 Feb 2012 15:30:01 EST news249744173 Treating women with early stage breast cancer with a combination of chemotherapy and the molecularly targeted drug Herceptin significantly increases survival in patients with a specific genetic mutation that results in very aggressive disease, a researcher with UCLA's Jonsson Comprehensive Cancer Center reported Wednesday. http://medicalxpress.com/news/2011-10-survival-early-stage-breast-cancer.html Cancer Wed, 05 Oct 2011 17:54:07 EST news237056037 An experimental two-drug combination for treating late-stage ovarian cancer continues to produce strong results, leading its Indiana University researchers to actively pursue the next step, conducting a larger clinical trial to test the therapy and to see how it compares with existing treatments for ovarian cancer. http://medicalxpress.com/news/2011-08-late-stage-ovarian-cancer-therapy-phase.html Cancer Wed, 03 Aug 2011 14:10:01 EST news231598840 Dose-dense chemotherapy has shown promise in smaller clinical trials, and now is being investigated in a multi-center, phase III study in which nearly 700 women will participate. Earlier phase II trials pointed to anti-cancer effects for the treatment approach, even when ovarian cancers had become resistant to standard treatment. http://medicalxpress.com/news/2011-06-ovarian-cancer-outcomes-dose-dense-chemotherapy.html Cancer Thu, 30 Jun 2011 09:23:51 EST news228644565 Faults in a gene commonly inactivated in many different types of cancer could be used to predict which drug combination ovarian cancer patients are most likely to benefit from, according to research at Newcastle University. http://medicalxpress.com/news/2011-06-gene-fault-ovarian-cancer-drug.html Cancer Mon, 06 Jun 2011 07:12:24 EST news226563000